Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma is executing a high-velocity commercial ramp, with 38.3% YoY revenue growth and a forward P/E of 21.7x implying a dramatic profitability inflection from its current elevated trailing multiple — a setup that has attracted near-unanimous analyst bullishness (6 Buy, 1 Hold, 0 Sell). The company's specialty pharma portfolio, including its ready-to-use glucagon and testosterone products, provides durable differentiation in niche but defensible therapeutic categories. The key risk is that earnings normalization is still prospective; failure to convert revenue growth into sustained EPS beats could rapidly erode the premium valuation and analyst confidence.

• Upcoming quarterly earnings report providing first hard evidence of the implied forward P/E earnings inflection, with particular focus on gross margin expansion and EPS trajectory.
• Continued commercial penetration of the specialty product portfolio, with any upward revision to revenue guidance serving as a near-term re-rating catalyst given the 38.3% YoY growth baseline.
• Potential pipeline or partnership announcements leveraging Xeris's proprietary formulation technology, which could expand the addressable market and add valuation upside beyond current analyst targets.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →